Supplementary Table S4. Comparison of OS stratified by genotype and treatment group

Gene/SNP	Sunitinib vs Placebo: HR (95% CI); *P* unadjusted		
VEGFA rs699947	A/A	A/C	C/C
	0.86 (0.29–2.57);	1.29 (0.62–2.70);	1.01 (0.39–2.61);
	0.786	0.498	0.990
VEGFA rs833061	C/C	C/T	T/T
	0.86 (0.29–2.57);	1.25 (0.61–2.54);	1.01 (0.37–2.79);
	0.786	0.544	0.982
VEGFR1 rs9554320	A/A	A/C	C/C
	2.26 (0.49–10.35);	1.01 (0.53–1.93);	1.04 (0.39–2.78);
	0.283	0.973	0.931
VEGFR1 rs9582036	C/C	C/A	A/A
	5.00 (0.51–48.63);	1.04 (0.50–2.13);	1.08 (0.49–2.38);
	0.125	0.926	0.850
VEGFR2 rs2071559	T/T	T/C	C/C
	0.77 (0.28–2.13);	1.18 (0.57–2.45);	1.42 (0.53–3.79);
	0.614	0.654	0.479
VEGFR2 rs1870377	A/A	A/T	T/T
	–	1.45 (0.58–3.60);	0.88 (0.47–1.66);
		0.424	0.694
VEGFR3 rs6877011	C/C	C/G	G/G
	1.12 (0.65–1.93);	1.68 (0.37–7.52);	–
	0.686	0.494	
LOXL2 rs4872122	A/A	A/C	C/C

	0.52 (0.15–1.77);	1.45 (0.70–3.01);	1.14 (0.46–2.79);
	0.284	0.314	0.777
eNOS rs2070744	T/T	T/C	C/C
	1.17 (0.52–2.60);	1.14 (0.57–2.27);	0.77 (0.11–5.48);
	0.705	0.720	0.795
SH3GL2 rs10963287	C/C	C/T	T/T
	1.19 (0.59–2.42);	0.87 (0.39–1.97);	1.96 (0.33–11.75);
	0.625	0.747	0.455
CCDC26 rs60315789	–/–	–/TAT	TAT/TAT
	0.68 (0.16–2.86);	1.04 (0.54–2.02);	1.44 (0.55–3.79);
	0.600	0.908	0.456

HRs calculated using the unstratified Cox proportional hazards model. Two-sided *P* value from the unstratified log rank test.

Abbreviations: CI=confidence interval; DFS=disease-free survival; SNP=single nucleotide polymorphism; VEGFR=VEGF receptor.